BioCardia Secures $4.4M Financing to Extend Cash Runway into 2027
BCDA•BioCardia raised $4.4 million by selling 3,509,604 shares at $1.279 each, with no warrants issued. Net proceeds are expected to extend the company’s cash runway into the first quarter of 2027 beyond its planned Q4 2026 Japan PMDA submission.
1. Financing Details
BioCardia sold 3,509,604 shares at an average price of $1.279 on June 5, 2026, generating net proceeds of $4.4 million. No warrants were issued in this financing, minimizing immediate dilution while bolstering the balance sheet.
2. Cash Runway and Future Catalysts
The financing extends BioCardia’s cash runway into Q1 2027, covering activities through its planned Q4 2026 Japan PMDA submission. Full exercise of outstanding warrants from prior financings could further extend runway beyond regulatory approval and into initial commercial sales.
